England's Cancer Drugs Fund 'failed to deliver meaningful value to patients and society'

Analysis of the drugs that were approved for use by the NHS Cancer Drugs Fund (CDF) in England has shown that the fund was not good value for patients and society and may have resulted in patients suffering unnecessarily from toxic side effects of the drugs. In a study published in the leading cancer journal Annals of Oncology, researchers led by Dr Ajay Aggarwal, academic clinical oncologist at London School of Hygiene & Tropical Medicine (UK), and Professor Richard Sullivan, director of the Institute of Cancer Policy, King's College London (UK), looked at 29 drugs that had been approved for use through the CDF in January 2015 for 47 specific cancer conditions (or indications).
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news